Gold bars to be exempt from tariffs, White House clarifies
Phyllis Gotlib, President, International at American Well Corp (NYSE:AMWL), sold 4,958 shares of Class A Common Stock on July 1, 2025, at a price of $8.6271, for a total value of $42,773. The transaction comes as AMWL shows strong momentum, with the stock delivering a 78% return over the past year and trading near $8.40. According to InvestingPro analysis, AMWL appears undervalued based on its Fair Value estimates.
Following the transaction, Gotlib directly owns 136,891 shares of American Well Corp. She also indirectly owns 64,250 shares through her husband. The company maintains a strong financial position with more cash than debt on its balance sheet and a healthy current ratio of 2.92x.
The sale was executed to cover the tax liability arising from the vesting and settlement of restricted stock units, according to a footnote in the SEC filing. InvestingPro subscribers can access 11 additional key insights about AMWL, including detailed analysis of its financial health, profitability metrics, and growth prospects.
In other recent news, Amwell reported a 12% year-over-year increase in total revenue for the first quarter of 2025, reaching $66.8 million. Notably, the subscription software revenue surged by 30% to $32.2 million, highlighting a significant growth area for the company. Despite this positive revenue performance, the company continues to face challenges with ongoing losses, as reflected in their adjusted EBITDA, which improved but remained negative at -$12.2 million compared to -$45.6 million in the previous year. Amwell has set its revenue guidance for the full year 2025 between $250 million and $260 million, with an adjusted EBITDA forecast ranging from -$55 million to -$45 million.
The company anticipates achieving positive cash flow from operations by 2026. In a recent development, Amwell announced the appointment of Dan Zemanski as Chief Product and Technology Officer, bringing experience from Amazon (NASDAQ:AMZN) Healthcare. Additionally, Amwell has expressed confidence in renewing their Defense Health Agency contract, which has been a key contributor to their revenue growth. While the company faces economic uncertainties and competition in the digital healthcare space, its focus on expanding AI-driven solutions and consumer experience optimization remains strong.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.